CAR-Ts move beyond B-cell cancers to myeloma.
Dolgin E. Nat Biotechnol. 2017 Jul 12;35(7):599-601. doi: 10.1038/nbt0717-599.

The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.
Brayer J et al. Ther Adv Hematol. 2017 Jul;8(7):209-220. doi: 10.1177/2040620717710171. Epub 2017 Jun 28.

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J et al.  Hematol Oncol. 2017 Jul 6;10(1):137. doi: 10.1186/s13045-017-0501-4.

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Dimopoulos MA et al. Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14787. [Epub ahead of print].

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myelomain TOURMALINE-MM1.
Mateos MV et al. Haematologica. 2017 Jul 27. pii: haematol.2017.170118. doi: 10.3324/haematol.2017.170118. [Epub ahead of print].

Safety of ixazomib for the treatment of multiple myeloma.
Bonnet A et al. Expert Opin Drug Saf. 2017 Jul 12:1-8. doi: 10.1080/14740338.2017.1344212. [Epub ahead of print].

Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.
Al-Salama ZT et al. Target Oncol. 2017 Jun 28. doi: 10.1007/s11523-017-0504-7. [Epub ahead of print].